These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 9824788

  • 1. Effect of high-dose oral ganciclovir on didanosine disposition in human immunodeficiency virus (HIV)-positive patients.
    Jung D, Griffy K, Dorr A, Raschke R, Tarnowski TL, Hulse J, Kates RE.
    J Clin Pharmacol; 1998 Nov; 38(11):1057-62. PubMed ID: 9824788
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics of oral ganciclovir alone and in combination with zidovudine, didanosine, and probenecid in HIV-infected subjects.
    Cimoch PJ, Lavelle J, Pollard R, Griffy KG, Wong R, Tarnowski TL, Casserella S, Jung D.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Mar 01; 17(3):227-34. PubMed ID: 9495222
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The pharmacokinetics and safety profile of oral ganciclovir combined with zalcitabine or stavudine in asymptomatic HIV- and CMV-seropositive patients.
    Jung D, AbdelHameed MH, Teitelbaum P, Dorr A, Griffy K.
    J Clin Pharmacol; 1999 May 01; 39(5):505-12. PubMed ID: 10234599
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The pharmacokinetics and safety profile of oral ganciclovir in combination with trimethoprim in HIV- and CMV-seropositive patients.
    Jung D, AbdelHameed MH, Hunter J, Teitelbaum P, Dorr A, Griffy K.
    Br J Clin Pharmacol; 1999 Mar 01; 47(3):255-9. PubMed ID: 10215748
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects.
    Jung D, Dorr A.
    J Clin Pharmacol; 1999 Aug 01; 39(8):800-4. PubMed ID: 10434231
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers.
    Brown F, Banken L, Saywell K, Arum I.
    Clin Pharmacokinet; 1999 Aug 01; 37(2):167-76. PubMed ID: 10496303
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Didanosine reduces atevirdine absorption in subjects with human immunodeficiency virus infections.
    Morse GD, Fischl MA, Shelton MJ, Borin MT, Driver MR, DeRemer M, Lee K, Wajszczuk CP.
    Antimicrob Agents Chemother; 1996 Mar 01; 40(3):767-71. PubMed ID: 8851608
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics of didanosine and ketoconazole after coadministration to patients seropositive for the human immunodeficiency virus.
    Knupp CA, Brater DC, Relue J, Barbhaiya RH.
    J Clin Pharmacol; 1993 Oct 01; 33(10):912-7. PubMed ID: 8227460
    [Abstract] [Full Text] [Related]

  • 18. Effects of didanosine formulations on the pharmacokinetics of amprenavir.
    Shelton MJ, Giovanniello AA, Cloen D, Berenson CS, Keil K, DiFrancesco R, Hewitt RG.
    Pharmacotherapy; 2003 Jul 01; 23(7):835-42. PubMed ID: 12885096
    [Abstract] [Full Text] [Related]

  • 19. CD4+ cell count decline despite HIV suppression: a probable didanosine-valganciclovir interaction.
    Tseng AL, Salit IE.
    Ann Pharmacother; 2007 Mar 01; 41(3):512-7. PubMed ID: 17341536
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.